Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Cancer · 2024

Tevimbra (tislelizumab-jsgr)

The FDA approved Tevimbra (tislelizumab-jsgr) on March 13, 2024 to treat unresectable or metastatic esophageal squamous cell carcinoma.
Brand name
Tevimbra
Generic name
tislelizumab-jsgr
FDA approval date
March 13, 2024
Approved use (FDA wording)
To treat unresectable or metastatic esophageal squamous cell carcinoma
Category on this site
Cancer

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.